Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
325
Enrollment
INDUSTRY
Sponsor class
Conditions
Spondyloarthropathies
Interventions
BIOLOGICAL:
CZP 200 mg Q2W
BIOLOGICAL:
CZP 400 mg Q4W
OTHER:
Placebo
Sponsor
UCB BIOSCIENCES GmbH